Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company's common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares.

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1.

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.

Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why

NEW YORK--(BUSINESS WIRE)---- $ZNTL #NYTop100--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL) into potential breaches of fiduciary duty by the Company's Board of Directors (the “Board”). Zentalis, headquartered in San Diego, CA, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways.

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Clients to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQ: ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today!

The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis announced on June 18, 2024, that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).

Levi & Korsinsky Reminds Zentalis Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL

NEW YORK CITY, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!

News for Zentalis Pharmaceuticals Stock (ZNTL)